BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 15536230)

  • 1. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.
    Astrup A; Caterson I; Zelissen P; Guy-Grand B; Carruba M; Levy B; Sun X; Fitchet M
    Obes Res; 2004 Oct; 12(10):1658-69. PubMed ID: 15536230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
    Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M;
    Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
    Bray GA; Hollander P; Klein S; Kushner R; Levy B; Fitchet M; Perry BH
    Obes Res; 2003 Jun; 11(6):722-33. PubMed ID: 12805393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension.
    Tonstad S; Tykarski A; Weissgarten J; Ivleva A; Levy B; Kumar A; Fitchet M
    Am J Cardiol; 2005 Jul; 96(2):243-51. PubMed ID: 16018851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topiramate: a new potential pharmacological treatment for obesity.
    Astrup A; Toubro S
    Obes Res; 2004 Dec; 12 Suppl():167S-73S. PubMed ID: 15687413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
    Rosenstock J; Hollander P; Gadde KM; Sun X; Strauss R; Leung A;
    Diabetes Care; 2007 Jun; 30(6):1480-6. PubMed ID: 17363756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H; Hamann A; Moore R; Masson E; Gorska M; Vercruysse F; Sun X; Fitchet M
    Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study.
    Silberstein SD; Hulihan J; Karim MR; Wu SC; Jordan D; Karvois D; Kamin M
    Clin Ther; 2006 Jul; 28(7):1002-11. PubMed ID: 16990078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phentermine/topiramate for the treatment of obesity.
    Smith SM; Meyer M; Trinkley KE
    Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
    Gadde KM; Parker CB; Maner LG; Wagner HR; Logue EJ; Drezner MK; Krishnan KR
    Obes Res; 2001 Sep; 9(9):544-51. PubMed ID: 11557835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
    Davidson MH; Tonstad S; Oparil S; Schwiers M; Day WW; Bowden CH
    Am J Cardiol; 2013 Apr; 111(8):1131-8. PubMed ID: 23375187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
    Kiortsis DN
    Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
    Tremblay A; Chaput JP; Bérubé-Parent S; Prud'homme D; Leblanc C; Alméras N; Després JP
    Eur J Clin Pharmacol; 2007 Feb; 63(2):123-34. PubMed ID: 17200837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.